ValuEngine upgraded shares of Replimune Group (NASDAQ:REPL) from a hold rating to a buy rating in a research report report published on Monday morning, ValuEngine reports.

Other analysts have also recently issued research reports about the company. Wedbush initiated coverage on Replimune Group in a research report on Wednesday, April 24th. They set an outperform rating and a $24.00 target price on the stock. Zacks Investment Research raised Replimune Group from a hold rating to a buy rating and set a $16.00 target price on the stock in a research report on Wednesday, July 3rd. Chardan Capital initiated coverage on Replimune Group in a research report on Tuesday, July 23rd. They set a buy rating and a $28.00 target price on the stock. JPMorgan Chase & Co. raised Replimune Group from a neutral rating to an overweight rating and dropped their target price for the company from $27.00 to $26.00 in a research report on Friday, July 12th. Finally, HC Wainwright initiated coverage on Replimune Group in a research report on Monday, July 8th. They set a buy rating and a $26.00 target price on the stock. Six analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $24.00.

Shares of NASDAQ REPL opened at $10.40 on Monday. The company has a current ratio of 14.26, a quick ratio of 14.26 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $331.86 million and a PE ratio of -7.82. The stock’s fifty day simple moving average is $12.73 and its two-hundred day simple moving average is $13.70. Replimune Group has a 12-month low of $8.88 and a 12-month high of $23.55.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. On average, equities analysts predict that Replimune Group will post -1.5 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Replimune Group in the 1st quarter worth $38,000. Rhumbline Advisers acquired a new stake in shares of Replimune Group in the 1st quarter worth $174,000. Morgan Stanley boosted its position in shares of Replimune Group by 793.0% in the 2nd quarter. Morgan Stanley now owns 20,709 shares of the company’s stock worth $304,000 after purchasing an additional 18,390 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Replimune Group by 211.3% in the 2nd quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock worth $338,000 after purchasing an additional 15,672 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Replimune Group by 21.2% in the 4th quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock worth $240,000 after purchasing an additional 4,209 shares in the last quarter. 59.59% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Story: Moving Average (MA)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.